Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 214, Issue 5, Pages 732-738Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiw233
Keywords
rotavirus; genotype; prevalence; surveillance; vaccine
Categories
Funding
- CDC
Ask authors/readers for more resources
Background. Group A rotaviruses (RVA) are a significant cause of pediatric gastroenteritis worldwide. The New Vaccine Surveillance Network (NVSN) has conducted active surveillance for RVA at pediatric hospitals and emergency departments at 3- 7 geographically diverse sites in the United States since 2006. Methods.aEuro integral Over 6 consecutive years, from 2008 to 2013, 1523 samples from NVSN sites that were tested positive by a Rotaclone enzyme immunoassay were submitted to the Centers for Disease Control and Prevention for genotyping. Results.aEuro integral In the 2009, 2010, and 2011 seasons, genotype G3P[8] was the predominant genotype throughout the network, with a 46%-84% prevalence. In the 2012 season, G12P[8] replaced G3P[8] as the most common genotype, with a 70% prevalence, and this trend persisted in 2013 (68.0% prevalence). Vaccine (RotaTeq; Rotarix) strains were detected in 0.6%-3.4% of genotyped samples each season. Uncommon and unusual strains (eg, G8P[4], G3P[24], G2P[8], G3P[4], G3P[6], G24P[14], G4P[6], and G9P[4]) were detected sporadically over the study period. Year, study site, and race were found to be significant predictors of genotype. Conclusions.aEuro integral Continued active surveillance is needed to monitor RVA genotypes in the United States and to detect potential changes since vaccine licensure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available